


## T cell proliferation activity of "Tactimab™" (anti-CD3 monoclonal antibody).

Comparative study of T cell growth stimulation activity between Tactimab and commercial available OKT3 antibody.

Method :


Lymphocytes collected from the blood of three healthy volunteers (A, B, C) were innoculated at  $1 \times 10^7$  cells/flask in a culture flask pretreated with **Tactimab** and OKT3 separately, and then cultured for 4 days in a culture solution containing IL-2. Cultured.

After 4 days of culture, the number of cells in each flask was measured, and the cell surface marker antigen was analyzed by flow cytometry.



Exp. 1 : Comparison of cell growth activity .

As shown in the figure, there was no difference in cell proliferation activity after 4 days culture between **Tactimab** and OKT-3.



Exp. 2 : Comparison of surface marker antigens of cultured lymphocytes.

As shown in the figure, there was no difference in the expression rate of cell markers CD4, CD8, CD56 and γδ in cells cultured with **Tactimab** and OKT3-M.

Summary: "**Tactimab™**" from Cell Science Inc., Ltd. had the same performance as a conventional OKT3 antibody. There was no difference in cell proliferation activity.